The State of the American Stem Cell Industry In 2012: Publicly Traded U.S. Stem Cell Companies By the Numbers
Published by Busa Consulting LLC, February 2013
The target audience for this report includes investors (individual, private equity, and venture capital), entrepreneurs and businesses in or serving the stem cell industry, and others with interests in the business of stem cell-based regenerative medicine or R&D.
|Price: $495 USD|
Topics Include:EXECUTIVE SUMMARY
STEM CELL CONCEPTS
THE SCSI FOURTEEN: DATA & PORTRAITS
HIGHLIGHTS FOR NON-SCSI COMPONENTS IN 2012
Excerpts From The Executive Summary:
A positive performance after last year’s steep losses, but still lagging
In 2012 the SCSI pulled out of its steep decline of the previous year and eked out a respectable gain (+10%, versus 2011’s -41%). Gainers increased to 8 out of 14 from last year’s 3. Nevertheless, the SCSI continued to lag well behind the S&P 500 for the 2011-2012 period.
Some big winners soared on just modestly good news
Stock-heavy deal flow continued
Institutional investors nearly doubled their stake in the market, but are still just testing the water
The majority of SCSI component companies cannot claim any significant investment by institutions.
Funding improved...but effective use of funds may be far from universal
Dilutive financing activities grew shares outstanding, and government-awarded R&D grants and contracts were up substantially. R&D spends were low given the very high cost of technology development and clinical trials - but a few SCSI component companies spent very little indeed. CEO and director compensation varied widely across companies, including some difficult to explain anomalies.
With most companies now in clinical trials, leading cell types and indications are becoming clearer
The market remains at the mercy of speculators
Very high market volatility driven by frequent overreactions to modest news, investors’ generally high tolerance of share dilution, and relatively low participation by institutional investors all suggest that stem cell share prices are still largely driven by speculators
About the Author
Following more than a decade as an NIH-funded faculty member in cell biology at the Johns Hopkins University, Dr. William Busa (President of Busa Consulting LLC) served as Vice President and Chief Scientific Officer of Cellomics Inc., the originator and industry leader in high content cell-based screening technology for pharmaceutical drug discovery. His tenure at Cellomics spanned the company's growth from a pre-revenue start-up to an operating company of over 100 FTEs, acquired by Fisher Scientific (now Thermo Fisher) in 2005. He also served as Director of Cell & Tissue Technologies at Becton Dickinson and Company's global R&D center, where he led technical and business collaborations with major pharmaceutical and regenerative medicine companies, guided the formulation of the company's 'cell therapy enablement' strategy, and led an organization bringing cell analysis and stem cell-related products to market.
Dr. Busa is an elected Fellow of the American Association for the Advancement of Science (AAAS). He has published over twenty peer-reviewed scientific publications in the fields of developmental cell biology and signal transduction biology, and is an inventor on multiple patents and patent applications related to cellular analysis.
|Price: $495 USD|
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. At the time of publication neither Busa Consulting LLC nor any of its employees had any business relationships with companies named in this report, nor held any equity positions, long or short, in any of the stocks discussed in this report, and did not anticipate taking any such positions within the following thirty days.